Advertisement
U.S. markets open in 8 hours 45 minutes
  • S&P Futures

    5,110.00
    +6.25 (+0.12%)
     
  • Dow Futures

    39,061.00
    +18.00 (+0.05%)
     
  • Nasdaq Futures

    18,120.00
    +37.25 (+0.21%)
     
  • Russell 2000 Futures

    2,057.60
    +0.30 (+0.01%)
     
  • Crude Oil

    78.54
    +0.28 (+0.36%)
     
  • Gold

    2,053.30
    -1.40 (-0.07%)
     
  • Silver

    22.93
    +0.05 (+0.20%)
     
  • EUR/USD

    1.0815
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    4.2520
    0.0000 (0.00%)
     
  • Vix

    13.40
    -0.44 (-3.18%)
     
  • GBP/USD

    1.2627
    +0.0001 (+0.01%)
     
  • USD/JPY

    150.4450
    +0.4610 (+0.31%)
     
  • Bitcoin USD

    61,494.21
    -639.26 (-1.03%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,630.02
    +5.04 (+0.07%)
     
  • Nikkei 225

    39,918.86
    +752.67 (+1.92%)
     

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

Sight Sciences, Inc.
Sight Sciences, Inc.

MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2023, after the market close on Thursday, August 3, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System technology is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD) when used in conjunction with manual expression of the meibomian glands, enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit http://www.sightsciences.com.

OMNI and TearCare are registered trademarks of Sight Sciences. SION is a trademark of Sight Sciences.
© 2023 Sight Sciences. All rights reserved.

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com


Advertisement